← Back to Search

Cancer Vaccine

STAVs + Dendritic Cell Vaccine for Aggressive Relapsed/Refractory Leukemias

Phase 1
Waitlist Available
Led By Juan C Ramos, MD
Research Sponsored by Juan C. Ramos, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial is investigating whether a combination of STING-dependent Adjuvants and dendritic cell vaccine therapies can help the body fight aggressive leukemias that have come back or haven't responded to treatment.

Eligible Conditions
  • Leukemia
  • Adult T-Cell Leukemia/Lymphoma
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Treatment-Related Adverse events
Secondary outcome measures
Failure-free survival (FFS) rate
Overall survival (OS)
Percentage of Participants Achieving Clinical Complete Response (CR)
+4 more

Side effects data

From 2013 Phase 2 trial • 11 Patients • NCT00323115
10%
Pain, neck, unilateral, Grade 2
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vaccine

Trial Design

1Treatment groups
Experimental Treatment
Group I: Combination STAVs and DC Vaccine GroupExperimental Treatment2 Interventions
Participants will receive STAV-loaded cells for a total of 5 doses on Days 3, 17, 31, 45 and 59. Participants will also receive up to 4 doses of dendritic vaccine on Days 10, 17, 24 and 31.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dendritic Cell Vaccine
2011
Completed Phase 2
~140

Find a Location

Who is running the clinical trial?

Juan C. Ramos, MDLead Sponsor
Juan C Ramos, MDPrincipal InvestigatorUniversity of Miami
1 Previous Clinical Trials
10 Total Patients Enrolled
1 Trials studying Leukemia
10 Patients Enrolled for Leukemia

Media Library

Dendritic Cell Vaccine (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05321940 — Phase 1
Leukemia Research Study Groups: Combination STAVs and DC Vaccine Group
Leukemia Clinical Trial 2023: Dendritic Cell Vaccine Highlights & Side Effects. Trial Name: NCT05321940 — Phase 1
Dendritic Cell Vaccine (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05321940 — Phase 1
~0 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top